Gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs

被引:94
作者
Jones, Roger [4 ]
Rubin, Greg [1 ]
Berenbaum, Francis [2 ]
Scheiman, James [3 ]
机构
[1] Univ Sunderland, Dept Primary Hlth Care, Sunderland SR2 7EE, Durham, England
[2] Univ Paris 06, Dept Med, APHP St Antoine, Paris, France
[3] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA
[4] Kings Coll London, Guys Hosp, Sch Med, Dept Gen Practice & Primary Care, London SE11 6SP, England
关键词
cardiovascular symptoms; gastrointestinal symptoms; gastroprotection; morbidity; mortality; nonsteriodal anti-inflammatory drugs; risks;
D O I
10.1016/j.amjmed.2008.01.045
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely prescribed but can have serious gastrointestinal (GI) and cardiovascular side effects, which have led to the withdrawal of some of these drugs and continuing uncertainty about the best approach to patients requiring NSAID therapy, particularly in those with GI or cardiovascular risk factors. To define the risks to the GI and cardiovascular systems associated with NSAID therapy, we have undertaken a series of systematic reviews of original articles published between January 1995 and December 2006. In this article we describe the mechanisms and patterns of GI and cardiovascular side effects in NSAID-taking patients and identify a range of drug and patient factors that contribute to an increased risk of adverse events. We conclude that NSAID therapy should not be started unless it is essential, and that Helicobacter pylori eradication should be considered in patients at increased GI risk. We discuss the use of gastroprotective agents and provide practical advice to help physicians assess and balance both cardiovascular and GI risks and benefits in their prescribing decisions. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:464 / 474
页数:11
相关论文
共 100 条
[1]
Aldington Sarah, 2005, N Z Med J, V118, pU1755
[2]
Aldington Sarah, 2005, N Z Med J, V118, pU1684
[3]
Ares JJ, 1998, CURR PHARM DESIGN, V4, P17
[4]
NONSTEROIDAL ANTIINFLAMMATORY DRUGS AND LIFE THREATENING COMPLICATIONS OF PEPTIC-ULCERATION [J].
ARMSTRONG, CP ;
BLOWER, AL .
GUT, 1987, 28 (05) :527-532
[5]
Exercise as a treatment for osteoarthritis [J].
Bennell, K ;
Hinman, R .
CURRENT OPINION IN RHEUMATOLOGY, 2005, 17 (05) :634-640
[6]
RANITIDINE PROTECTS AGAINST GASTRODUODENAL MUCOSAL DAMAGE ASSOCIATED WITH CHRONIC ASPIRIN THERAPY [J].
BERKOWITZ, JM ;
ROGENES, PR ;
SHARP, JT ;
WARNER, CW .
ARCHIVES OF INTERNAL MEDICINE, 1987, 147 (12) :2137-2139
[7]
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[8]
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].
Bresalier, RS ;
Sandler, RS ;
Quan, H ;
Bolognese, JA ;
Oxenius, B ;
Horgan, K ;
Lines, C ;
Riddell, R ;
Morton, D ;
Lanas, A ;
Konstam, MA ;
Baron, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102
[9]
Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis [J].
Caldwell, B ;
Aldington, S ;
Weatherall, M ;
Shirtcliffe, P ;
Beasley, R .
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2006, 99 (03) :132-140
[10]
Prospective randomized trial of H-pylori eradication versus maintenance omeprazole to prevent recurrent upper gastrointestinal hemorrhage in high-risk aspirin and non-aspirin NSAID users. [J].
Chan, FK ;
Sung, JJ ;
Suen, BY ;
Wu, JC ;
Leung, VK ;
Lai, MS ;
Leung, WK ;
Hui, Y ;
Lee, YT ;
Chung, S .
GASTROENTEROLOGY, 2000, 118 (04) :A194-A194